Twiist Insulin Pump Release Date and Features

The Twiist insulin pump release date keeps showing up in diabetes forums, Facebook groups, and clinic waiting rooms. People want to know when this device will actually be in their hands, what it will cost, and whether it is worth waiting for instead of starting on a current pump.

This post pulls together everything we know so far from Sequel Med Tech, FDA submissions, industry coverage, and clinical trial activity. The Twiist is still an upcoming device, and details are likely to shift between now and commercial launch. Where we are not certain, we say so.

If you are weighing whether any pump fits your life right now, our insulin pump guide covers the broader decision before you start tracking specific products.

#Twiist Insulin Pump Release Date: Latest Updates

The Twiist insulin pump release date is a moving target. As of early 2026, Sequel Med Tech has confirmed the device received FDA 510(k) clearance in March 2024 and began a phased commercial rollout through select diabetes clinics in late 2024. Wider US availability is expanding through 2025 and into 2026, with international launches still in planning.

Sequel is taking a deliberately slow rollout approach, training clinics one region at a time rather than going to a national launch on day one. This is a common pattern for new pumps, partly because clinical staff need product training before they can prescribe and partly because supply chains for infusion sets and reservoirs ramp gradually.

For US patients, the practical answer to "when can I get a Twiist" depends on whether your endocrinology clinic is one of the early adopter sites. Sequel maintains a clinic locator and a patient interest list on their website. Joining the list does not commit you to anything, but it puts you in the queue for prior authorization paperwork once your area opens up.

#Sequel Med Tech Background

Sequel Med Tech is a Manchester, New Hampshire company founded by former Insulet engineers, several of whom worked on early generations of the OmniPod. That background shows up in the Twiist's design philosophy, which favors small form factor and tight CGM integration over heavy onboard programming.

The company raised significant venture funding in 2022 and 2023 to support the FDA submission and manufacturing scale-up. Industry coverage from outlets like DiabetesMine and Healthline through 2024 has tracked the Twiist's development from prototype to FDA-cleared product.

#How the Timeline Compares to Other Recent Launches

For context, the iLet bionic pancreas from Beta Bionics took about 8 years from first clinical trials to commercial launch in 2023. The Tandem Mobi launched in 2024 after a similar multi-year development. The Twiist is following a comparable timeline, which is fairly normal for class III medical devices.

What is different about the Twiist is the depth of CGM integration the company has built in from the start. Rather than treating the CGM as a separate system, Sequel designed the pump and the algorithm assuming continuous Dexcom data is always available.

#Twiist Insulin Pump Features and Specs

Based on FDA submissions, Sequel Med Tech product materials, and clinical trial publications, here is what the Twiist insulin pump for type 1 diabetes is shaping up to offer at commercial launch. Some details are confirmed, others are projected, and we mark each clearly.

The form factor is a tubed pump with a slim, modern profile. The device is approximately 2.7 inches by 1.6 inches by 0.6 inches, which is smaller than the Tandem t:slim X2. Total weight is around 1.4 ounces empty, in the same general range as other modern tubed pumps.

The reservoir holds 300 units of U-100 insulin, matching the Tandem t:slim and the Medtronic 780G. This is a meaningful upgrade over the iLet's 180-unit reservoir, especially for people with higher daily insulin needs.

#Touchscreen, App, and Connectivity

The Twiist uses a small color touchscreen with a deliberately simplified interface. Most user interactions, including bolusing, history review, and settings adjustments, also work through a paired smartphone app. The app handles cloud sync, sharing data with caregivers, and clinic uploads to systems like Glooko and Tidepool.

Bluetooth Low Energy connects the pump to a Dexcom G7 sensor and to the smartphone app. Sequel has stated they may add support for additional CGMs after launch, though G7 is the only CGM cleared at the initial release.

The pump runs an automated insulin delivery algorithm that adjusts basal delivery and delivers automatic correction boluses based on CGM trends. This is a hybrid closed-loop approach similar to Tandem's Control-IQ, where you and your provider set basal rates, carb ratios, and correction factors as a baseline and the algorithm modulates around them. NIDDK's overview of insulin medicines and treatments describes how artificial pancreas systems combine pump, CGM, and algorithm to keep glucose in target.

#Infusion Sets and Battery

The Twiist uses a proprietary infusion set system with 6mm and 9mm cannula options and standard tubing lengths. Sets are sold directly through Sequel's pharmacy network. The pump uses a rechargeable battery rated for approximately 5 to 7 days per charge, and charging happens through a small wireless dock.

#What Makes the Twiist Different From Current Pumps

The most-discussed Twiist feature is size. At about 30 percent smaller than a Tandem t:slim X2, the Twiist is one of the smallest tubed pumps on the market. For people who currently feel self-conscious wearing a pump or struggle to find clothing pockets that fit a t:slim, the size difference matters in daily life.

The benefits of insulin pump therapy at smaller form factors include better wearability under fitted clothing, less visibility in social or professional settings, and easier carry during exercise. Whether the Twiist's size advantage is worth switching pumps depends on how much your current device's bulk bothers you day to day.

Another differentiator is the smartphone-first user experience. Tandem and Medtronic have added phone apps over the years, but the Twiist was designed app-first from the start. You can bolus, review CGM trends, and adjust settings without ever pulling the pump out from under your clothes.

#Algorithm Approach

The Twiist's hybrid closed-loop algorithm is conventional in approach but tunable in practice. Sequel has emphasized customization options for activity, sleep, and meal handling that go a step beyond the current Control-IQ profiles. Whether those features deliver real-world improvements over the t:slim or the OmniPod 5 is the key question for clinicians evaluating the pump.

If you are not familiar with how AID systems work, our artificial pancreas systems post explains the underlying technology in plain language.

#Connectivity and Caregiver Features

The Twiist app supports remote follow features for caregivers, similar to Dexcom Follow. Parents of kids with type 1 can see CGM data, bolus history, and insulin on board on their own phone in near real time. This is increasingly standard across pumps but worth confirming as you compare options.

Cloud data sync is automatic and integrates with Glooko, Tidepool, and Sequel's own clinic-facing platform. Clinic visits with a Twiist tend to involve less device-to-laptop cable shuffling than with older pumps.

#How the Twiist Compares to Existing Pumps

Here is a side-by-side projection of how the Twiist may stack up against the most common AID pumps available now. Specs marked "projected" are based on Sequel publications and may shift before broad commercial availability.

For a different point of comparison, see our iLet bionic pancreas review, which takes a fundamentally different algorithm approach. Our OmniPod review covers the leading tubeless option in depth.

#Price Expectations

Sequel has not published list pricing publicly, but industry coverage suggests the Twiist will fall in line with other premium AID pumps in the $5,500 to $7,000 list price range. For most insured patients, out-of-pocket costs depend on durable medical equipment benefits and prior authorization, not the list price.

Ongoing supply costs (infusion sets, reservoirs, Dexcom G7 sensors) are likely to be comparable to Tandem and Medtronic. The American Diabetes Association includes AID systems in its Standards of Care recommendations, which strengthens insurance coverage arguments across the board.

#Should You Wait for the Twiist

The buy-now-or-wait question is one of the most common in pump therapy decisions, and the honest answer depends on three factors: how your current diabetes management is going, when your insurance allows pump replacement, and how much waiting will cost in time-in-range.

If your current management on MDI is producing A1Cs in your goal range, your insurance will not approve a pump for another 12 to 18 months, and you have low risk of severe lows, waiting may be reasonable. The Twiist is real, the FDA cleared it, and Sequel is shipping. By 12 months from now, real-world reviews and clinic experience will be substantial.

If your current pump is more than 4 years into its 4-year warranty, your insurance is open to a replacement, and you are dealing with frequent highs or lows, waiting probably costs more than it saves. Switching to a current AID pump now and re-evaluating at your next replacement cycle is usually the better path.

#Insurance Timing

Most US commercial insurance plans cover a new pump every 4 to 5 years through DME benefits. The prior authorization process can take 4 to 12 weeks depending on the plan and the provider. If you want to be among the first to try a Twiist when it reaches your area, start asking your endocrinology clinic about the process now so you are not standing in a paperwork queue when supply opens up.

Medicare Part B has its own coverage rules, with replacement typically allowed every 5 years. Medicaid varies state by state.

#Staying on Your Current Pump

If you are happy with your current pump, do not feel pressure to switch just because the Twiist is interesting. The Tandem t:slim X2, OmniPod 5, Medtronic 780G, and iLet are all clinically validated systems producing strong outcomes. The Twiist may eventually offer a better experience for your specific needs, but it will need a year or two of real-world data before that picture is clear.

From my experience: I have been on three pumps across 14 years with type 1, and each transition came with a learning curve I underestimated. New pumps are exciting, but the first 4 to 6 weeks on any new system tend to involve worse time-in-range than the last 4 weeks on the old one. If your current pump is working, the safest move is usually to ride out the warranty cycle and let the new device prove itself in the wild before you switch.

#FAQ

#When is the Twiist insulin pump release date?

The Twiist insulin pump received FDA clearance in March 2024 and began a phased commercial rollout through select US diabetes clinics in late 2024. Broader availability is expanding through 2025 and 2026, with the rollout reaching more clinics each quarter. Joining Sequel Med Tech's interest list and asking your endocrinology clinic if they are an early adopter site is the fastest way to find out when the Twiist will be available in your area.

#What features and specs will the Twiist have?

The Twiist insulin pump features a slim tubed form factor (about 30 percent smaller than a Tandem t:slim X2), a 300-unit insulin reservoir, smartphone app control for bolusing and settings, hybrid closed-loop automated insulin delivery, and Dexcom G7 CGM integration. The system supports caregiver remote-follow features and cloud data sync with Glooko and Tidepool. Specs may shift slightly between early launch and broader availability.

#Should I wait for the Twiist or buy a pump now?

Wait for the Twiist if your current diabetes management is going well, your insurance will not approve a pump for another 12 to 18 months anyway, and you have low risk of severe lows. Get a current pump now if your management is suffering, your warranty cycle is open, or you have frequent highs or lows that an AID system would help. The Twiist insulin pump release date is real, but new device adoption always involves trade-offs. Talk to your doctor about which timing fits your specific situation.

The Twiist is one of the more anticipated pump releases in years, and the first wave of real-world reviews from people who get it through clinic-led rollouts will tell us a lot. We will keep this post updated as Sequel Med Tech expands availability and as patient experience accumulates.